N-acetyl-D-mannosamine—a key carbohydrate building block in biosynthesis 7772-94-3

N-Acetyl-D-mannosamine (ManNAc) is a core precursor molecule in the biosynthesis of the sialic acid family and plays an indispensable role in basic research in life sciences, glycoprotein engineering, and the development of emerging therapies. As an important member of monosaccharide compounds, it is not only a key metabolic intermediate in the synthesis of sugar chains on the cell surface, but also has become a star molecule in the development of new therapeutic strategies and biological tools.

Chemical Information

Chemical name: N-acetyl-D-mannosamine

Common name: N-acetyl-D-mannosamine, ManNAc

Chemical formula: C₈H₁₅NO₆

Molecular weight: 221.21 g/mol

CAS number: 7772-94-3

Category: Monosaccharides

Structural features

N-acetyl-D-mannosamine is the N-acetylated form of D-mannosamine and belongs to the hexosamines structurally. Its unique features are:

Key biosynthetic precursor: ManNAc is the direct substrate for intracellular synthesis of sialic acid (such as N-acetylneuraminic acid, Neu5Ac). Through a series of enzymatic reactions, it is eventually converted into sialic acid, which is an important sugar residue at the termini of cell surface glycoproteins and glycolipids.

Flexible chemical modification sites: Functional groups such as hydroxyl and acetamido in its structure provide the possibility for chemical modification and derivatization, making it easy to introduce tags or functional groups for metabolic labeling and glycoengineering.

Good biocompatibility and metabolic activity: As a component of the natural metabolic pathway, exogenously added ManNAc can be effectively taken up and utilized by cells, providing an effective non-genetic engineering means for regulating cell surface glycosylation.

Main applications and advantages

1. Core tools for cell surface glycoengineering and glycoprotein optimization

Regulation of sialic acid expression: Exogenous supplementation of ManNAc can interfere with the intracellular sialic acid synthesis pathway and increase the level of sialylation on the cell surface. This is crucial to improve the pharmacokinetic properties of therapeutic proteins (e.g., antibodies, enzymes, hormones), such as extending their half-life in vivo and enhancing targeting.

Realize metabolic labeling: Using chemically modified ManNAc analogs (such as with azide or alkynyl groups), bioorthogonal groups can be introduced into cell surface sugar chains through metabolic oligosaccharide engineering technology, thereby achieving specific labeling, imaging, separation or functional regulation of glycoproteins, providing a powerful tool for glycomic research.

2. Disease model research and development of potential treatment strategies

Genetic disease research: ManNAc has been studied for the treatment of rare genetic diseases-sialic acidosis (such as GNE myopathy, also known as hereditary inclusion body myopathy). The disease is caused by a functional defect of the GNE/MNK enzyme in the sialic acid synthesis pathway. Oral administration of ManNAc has shown potential in clinical trials as a substrate supplementation therapy designed to bypass the defective enzyme and restore sialic acid synthesis.

Immunity and inflammation regulation: Cell surface sialic acid is a ligand of immune regulatory receptors (such as Siglecs) and participates in maintaining immune homeostasis. Regulation of sialylation by ManNAc can affect immune cell recognition and activation, providing new research ideas for autoimmune diseases, inflammation and cancer immunotherapy.

Antiviral and microbial infections: Many pathogens use sialic acid on the surface of host cells as receptors for invasion. Intervening the sialylation level of host cells through ManNAc may affect the attachment and infection process of viruses (such as influenza viruses, coronaviruses) or bacteria, providing a new perspective for anti-infection strategies.

3. Biomanufacturing and synthetic biology

Biosynthesis of sialic acid and its derivatives: ManNAc is a key starting material for the enzymatic or whole-cell catalytic production of high-value sialic acid and its derivatives, and is widely used in the green manufacturing of food, cosmetics and pharmaceutical intermediates.

Chassis cell metabolic engineering: Constructing a sialic acid synthesis pathway with ManNAc as an intermediate in microorganisms (such as E. coli and yeast) is one of the core technologies for the production of humanized glycoproteins, glycoconjugate vaccines or special carbohydrate compounds.

Conclusion

N-Acetyl-D-mannosamine is much more than a simple monosaccharide molecule. It is a bridge between basic glycobiology and cutting-edge biomedical applications, a key to exploring the "glycemic language" of cell surfaces, and a cornerstone for the development of next-generation glycosylation modification therapies and diagnostic tools. Whether it is advancing the treatment of rare metabolic diseases, optimizing the performance of biopharmaceuticals, or decoding complex intercellular communication mechanisms, ManNAc has demonstrated its unique and broad application value.

The above information is provided by the editor of KASONS and is for scientific research only.